NASDAQ: TCRT
Alaunos Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their TCRT stock forecasts and price targets.

Forecast return on equity

Is TCRT forecast to generate an efficient return?

Company
-11.37%
Industry
17.93%
Market
331.46%
TCRT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TCRT forecast to generate an efficient return on assets?

Company
-8.56%
Industry
13.14%
TCRT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TCRT earnings per share forecast

What is TCRT's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.88
Avg 2 year Forecast
-$0.14

TCRT revenue forecast

What is TCRT's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$568.1M+14,201,400%
Avg 2 year Forecast
$0.0-100%
TCRT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TCRT revenue growth forecast

How is TCRT forecast to perform vs Biotechnology companies and vs the US market?

Company
14,201,400%
Industry
9,700.42%
Market
1,464.38%
TCRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TCRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TCRT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TCRT$3.36N/AN/A
ADIL$0.31$1.50+383.87%Strong Buy
BGMS$1.50N/AN/A
ACXP$3.75$31.00+726.67%Buy
PHGE$4.70$26.00+453.19%Buy

Alaunos Therapeutics Stock Forecast FAQ

What is TCRT's earnings growth forecast for 2025-2026?

(NASDAQ: TCRT) Alaunos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 180.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,913.2%.

Alaunos Therapeutics's earnings in 2025 is -$4,025,000.On average, 4 Wall Street analysts forecast TCRT's earnings for 2025 to be $1,957,760, with the lowest TCRT earnings forecast at $1,880,985, and the highest TCRT earnings forecast at $2,015,342.

In 2026, TCRT is forecast to generate -$318,705 in earnings, with the lowest earnings forecast at -$306,207 and the highest earnings forecast at -$328,079.

If you're new to stock investing, here's how to buy Alaunos Therapeutics stock.

What is TCRT's revenue growth forecast for 2025-2026?

(NASDAQ: TCRT) Alaunos Therapeutics's forecast annual revenue growth rate of 14,201,400% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,700.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 1,464.38%.

Alaunos Therapeutics's revenue in 2025 is $4,000.On average, 4 Wall Street analysts forecast TCRT's revenue for 2025 to be $1,267,812,782, with the lowest TCRT revenue forecast at $1,218,109,950, and the highest TCRT revenue forecast at $1,305,106,644.

In 2026, TCRT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TCRT's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: TCRT) forecast ROA is -8.56%, which is lower than the forecast US Biotechnology industry average of 13.14%.

What is TCRT's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: TCRT) Alaunos Therapeutics's current Earnings Per Share (EPS) is -$2.31. On average, analysts forecast that TCRT's EPS will be $0.88 for 2025, with the lowest EPS forecast at $0.84, and the highest EPS forecast at $0.90. In 2026, TCRT's EPS is forecast to hit -$0.14 (min: -$0.14, max: -$0.15).

What is TCRT's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: TCRT) forecast ROE is -11.37%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.